Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant

Current Opinion in Hematology

Volumn 21, Issue 6, 2014, Pages 476-481

  Rouce, Rayne H ^a   Louis, Chrystal U ^a   Heslop, Helen E ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Epstein Barr virus; Post transplant lymphoproliferative disease; Stem cell transplant

Indexed keywords

ALEMTUZUMAB; MONOCLONAL ANTIBODY; RITUXIMAB; VIRUS DNA;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; B LYMPHOCYTE; CELLULAR IMMUNITY; CHEMOTHERAPY; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMORAL IMMUNE DEFICIENCY; INFECTION RISK; LYMPHOCYTE PROLIFERATION; MORBIDITY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; VIREMIA; VIRUS DETECTION; VIRUS LOAD; VIRUS REACTIVATION; ADVERSE EFFECTS; ALLOTRANSPLANTATION; EPSTEIN-BARR VIRUS INFECTIONS; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISORDERS; VIRUS ACTIVATION;

EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 84927582753     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000083     Document Type: Review

References (30)

1. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114:4002-4008.
2. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56:29-44.
3. Aalto SM, Juvonen E, Tarkkanen J, et al. Lymphoproliferative disease after allogeneic stem cell transplantation: preemptive diagnosis by quantification of Epstein-Barr virus DNA in serum. J Clin Virol 2003; 28:275-283.
4. Uhlin M, Wikell H, Sundin M, et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica 2014; 99:346-352.
5. Liu Q, Xuan L, Liu H, et al. Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. Am J Hematol 2013; 88:550-555.
6. Rooney CM, Loftin SK, Holladay MS, et al. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89:98-103.
7. van Esser JW, van der HB, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98:972-978.
8. Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103:3979-3981.
9. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43:757-770.
10. Cohen JM, Cooper N, Chakrabarti S, et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma 2007; 48:256-269.
11. Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108:2874-2880.
12. Patriarca F, Medeot M, Isola M, et al. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. Transpl Infect Dis 2013; 15:259-267.
13. Dumas PY, Ruggeri A, Robin M, et al. Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Societe Francaise de Greffe de Moelle-Therapie Cellulaire collaborative study. Bone Marrow Transplant 2013; 48:253-256.
14. Sanz J, Arango M, Senent L, et al. EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. Bone Marrow Transplant 2014; 49:397-402.
15. Li FY, Chaigne-Delalande B, Su H, et al. XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood 2014; 123:2148-2152.
16. Dominietto A, Tedone E, Soracco M, et al. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant 2012; 47:101-106.
17. van der Velden WJ, Mori T, Stevens WB, et al. Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating preemptive rituximab. Bone Marrow Transplant 2013; 48:1465-1471.
18. Fox CP, Burns D, Parker AN, et al. EBV-associated post-transplant lymphoproliferative disorder following in vivo T cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. Bone Marrow Transplant 2014; 49:280-286.
19. Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of posttransplant lymphoproliferative disease. Nat Rev Clin Oncol 2012; 9:510-519.
20. Styczynski J, Einsele H, Gil L, et al. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11:383-392.
21. Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012; 119:2644-2656.
22. Icheva V, Kayser S, Wolff D, et al. Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 2013; 31:39-48.
23. Gerdemann U, Katari UL, Papadopoulou A, et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 2013; 21:2113-2121.
24. Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after allogeneic HSCT. Science Transl Med 2014; 6:242ra83.
25. Wang Y, issi-Rothe L, Virion JM, et al. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy. Cytotherapy 2014; 16:122-134.
26. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110:1123-1131.
27. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked thirdparty virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013; 121:5113-5123.
28. Gallot G, Vollant S, Saiagh S, et al. T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study. J Immunother 2014; 37:170-179.
29. Ricciardelli I, Brewin J, Lugthart G, et al. Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy. Am J Transplant 2013; 13:3244-3252.
30. Papadopoulou A, Krance RA, Allen CE, et al. Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther 2014; 22:1134-1138.